21734-85-0

Basic information

• Product Name: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE
• Synonyms: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE;5-Chlor-3-methyl-[1,2,4]thiadiazol;1,2,4-Thiadiazole, 5-chloro-3-methyl-
• CAS NO: 21734-85-0
• Molecular Formula: C₃H₃ClN₂S
• Molecular Weight: 134.59
• Mol File: 21734-85-0.mol

Chemical Properties

• Boiling Point: 221.475 °C at 760 mmHg
• Flash Point: 87.745 °C
• Appearance: /
• Density: 1.438 g/cm³
• Vapor Pressure: 0.159mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.36±0.10(Predicted)
• CAS DataBase Reference: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE(21734-85-0)
• EPA Substance Registry System: 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE(21734-85-0)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 21734-85-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE is used as an intermediate in the synthesis of various pharmaceuticals. Its antimicrobial and antifungal properties make it a valuable component in the development of new drugs for the treatment of various diseases.
Used in Agrochemical Industry:
In the agrochemical industry, 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE is utilized as an intermediate for the production of pesticides. Its antimicrobial and antifungal properties help in controlling pests and diseases in crops, thereby improving agricultural productivity.
Used in Antiseptic Production:
5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE is used as an active ingredient in the production of antiseptics. Its antimicrobial properties help in preventing infections and promoting wound healing.
It is important to handle 5-CHLORO-3-METHYL-1,2,4-THIADIAZOLE with care and follow proper safety protocols due to its potential health hazards.

InChI:InChI=1/C3H3ClN2S/c1-2-5-3(4)7-6-2/h1H3

Upstream product

• 75-09-2 dichloromethane 
• 623-11-0 1-methyl-4-nitrosobenzene 
• 124-42-5 acetamidine hydrochloride 
• 594-42-3 chlorothio-trichloro-methane 
• 143-37-3 acetamidine 
• 20846-52-0 2-chloro-acetamidine 
• 75-70-7 trichloromethyl mercaptan 

Downstream Products

• 36988-21-3 3-methyl-4H-[1,2,4]thiadiazole-5-thione 
• 35550-13-1 5-Methylamino-3-methyl-1,2,4-thiodiazol 
• 21735-09-1 3-methyl-5-(4-nitro-benzenesulfonyl)-[1,2,4]thiadiazole 
• 21735-11-5 N-[4-(3-methyl-[1,2,4]thiadiazole-5-sulfonyl)-phenyl]-acetamide 
• 17467-17-3 cyclohexyl-(3-methyl-[1,2,4]thiadiazol-5-yl)-amine 
• 17467-19-5 N-(4-chlorophenyl)-3-methyl-1,2,4-thiadiazol-5-amine 
• 17467-18-4 3-methyl-N-phenyl-1,2,4-thiadiazol-5-amine 
• 17467-37-7 (3-chloro-phenyl)-(3-methyl-[1,2,4]thiadiazol-5-yl)-amine 
• 17467-36-6 (2-chloro-phenyl)-(3-methyl-[1,2,4]thiadiazol-5-yl)-amine 
• 21735-14-8 4-acetylamino-N-(3-methyl-[1,2,4]thiadiazol-5-yl)-benzenesulfonamide 
• 90920-64-2 4-(3-methyl-[1,2,4]thiadiazol-5-ylamino)-benzonitrile 
• 38362-20-8 5-Hydrazino-3-methyl-1,2,4-thiadiazol 
• 17467-35-5 3-methyl-1,2,4-thiadiazol-5-amine 
• 37864-85-0 3-Methyl-5-methylsulfonyl-1,2,4-thiadiazol 

Relevant articles and documents

HETEROARYL SUBSTITUTED PIPERIDINES

The invention relates to compounds of formula where hetaryl I, hetaryl II, R1,R2,R3, R4, m, n, and o are as defined in the specification or to pharmaceutically active acid addition salts thereof. The compounds of formula I are modulators for amyloid beta and thus may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

PIPERIDINE DERIVATIVES

The invention relates to compounds of formula (I). Hetaryl I is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; hetaryl II is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N, or is a two membered ring system containing 1 to 4 heteroatoms selected from S, O or N, wherein at least one ring is aromatic in nature; R1 is lower alkyl, lower alkoxy, lower alkyl substituted by halogen, or halogen; R2 is halogen, lower alkyl, lower alkoxy, hydroxy, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or benzo[1,3]dioxolyl, or is -(CHR)p-phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy, S(O)2 -1ower alkyl, cyano, nitro, lower alkoxy substituted by halogen, dimethylamino, -(CH2)P-NHC(O)O-Iower alkyl, or lower alkyl substituted by halogen, and R is hydrogen, halogen, hydroxy or lower alkoxy, or is cycloalkenyl or cycloalkyl, optionally substituted by hydroxy or lower alkyl substituted by halogen, or is a five or six membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N, which is optionally substituted by halogen, lower alkyl, lower alkoxy or dimethylamino, or is O-phenyl, optionally substituted by halogen, or is heterocycloalkyl, optionally substituted by halogen, hydroxy, lower alkyl substituted by halogen or C(O)O-lower alkyl; R3 is hydrogen, lower alkyl, cyano or phenyl; R4 is lower alkoxy, lower alkyl or halogen; p is 0 or 1; n is 0, 1 or 2; if n is 2 then R4 may be the same or different; m is 0, 1 or 2; if m is 2 then R1 may be the same or different; o is 0, 1, 2 or 3, if o is 2 or 3 then R2 may be the same or different; or to pharmaceutically active acid addition salts thereof. The compounds of formula (I) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of beta- amyloid in the brain, in particular Alzheimer?s disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome

HISTONE DEACETYLASE INHIBITORS

The present invention provides histone deacetylase inhibitors of general formula (I), a process for the preparation of such compounds and uses of the compounds in medicine, especially in the treatment of cancers: in which R1 is an optionally su

MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS

The present invention relates to modulators of muscarnic receptors of formula (I). The present invention also provides impositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

1,2,4- THIADIAZOL-5-THIO COMPOUNDS AND THE DERIVATIVES THEREOF, METHODS FOR THE PRODUCTION THEREOF AND USE THEREOF AS UREASE AND NITRIFICATION INHIBITORS

The invention relates to methods for the production and use of novel 1,2,4-thiadiazols of general formulae (I) or (II) as agents for regulating the inhibition of enzymatic urea hydrolysis, wherein R1 = hydrogen, C1-C8-alkyl or C6-C10-aryl and R2 = hydrogen, C1-C8- alkyl/heteroalkyl, C2-C8 -alkenyl/heteroalkenyl, C2-C8 -alkinyl/heteroalkinyl, C3-C8- cycloalkyl/heterocycloalkyl, C3-C8 -cycloalkenyl/heterocycloalkenyl, C6-C10 -aryl/heteroaryl, aralkyl, heteroarylalkyl, alkaryl, akheteroaryl, alkoxy, aryloxy, hetaryloxy, alkylthio, arylthio, hetarylthio, acyl, aroyl, hetaroyl, acyloxy, aroyloxy, hetaroyloxy, alkoxycarbonyl, aryloxycarbonyl, hetaryloxycarbonyl, amino, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, fluorine, chlorine, bromine, iodine, hydroxy, cyano, nitro, sulfo, carbonyl, carboxy, carbamoyl, sulfamoyl, the radicals R1 and/or R2 can, optionally, be per se and individually substituted by one or several of the above-mentioned groups. With a limited spectrum of substituents in R2, said compounds can be claimed as nitrification inhibitors. The inventive 1,2,4-thiadiazols thus used are effective urease inhibitors and have a good resistance to hydrolysis and can be produced according to known methods. They are also effective nitrification inhibitors and can delay transformation of ammonia. They are the first inhibitors which effectively eliminate the two main sources of loss during the application of manure, i.e. urease-catalyzed urea hydrolysis and nitrification of ammonia nitrogen. The inventive compounds can also be combined with more potent nitrification inhibitors, whereby nitrogen losses can also be reduced, without any problem.

3-Heteroaryl-2-pyridones: Benzodiazepine site ligands with functional selectivity for α2/α3-subtypes of human GABAa receptor-ion channels

A novel series of 3-heteroaryl-5,6-bis(aryl)-1-methyl-2-pyridones were developed with high affinity for the benzodiazepine (BZ) binding site of human γ-aminobutyric acid (GABAA) receptor ion channels, low binding selectivity for α2- and/or α3- over α1-containing GABAA receptor subtypes and high binding selectivity over α5 subtypes. High affinity appeared to be associated with a coplanar conformation of the pyridone and sulfur-containing 3-heteroaryl rings resulting from an attractive S...O intramolecular interaction. Functional selectivity (i.e., selective efficacy) for α2 and/or α3 GABAA receptor subtypes over α1 was observed in several of these compounds in electrophysiological assays. Furthermore, an α3 subtype selective inverse agonist was proconvulsant and anxiogenic in rodents while an α2/α3 subtype selective partial agonist was anticonvulsant and anxiolytic, supporting the hypothesis that subtype selective BZ site agonists may provide new anxiolytic therapies.

(R,R) AND (S,S) 2,5-DIAZABICYCLO [2,2,1]HEPTANE DERIVATIVES

Compounds of the Formulae I or II STR1 wherein Z and R 1, are as described herein which compounds are muscarinic agonists useful in treating central cholinergic disfunction and pharmaceutical compositions containing the compounds.

Antisecretory thiadiazole derivatives, processes for their manufacture and pharmaceutical compositions containing them

The invention relates to a thiadiazole derivative of the formula I: STR1 in which Y is O, S, CH2, SO or a direct bond; m is 0 to 4 and n is 1 to 4 provided that when Y is S, O or SO m is 1 to 4, and when Y is O or SO n is 2 to 4; R1 is H or (C1-10)alkyl; A is 3,4-dioxocyclobuten-1,2-diyl or C=Z in which Z is O, S, NCN, NNO2, CHNO2, NCONH2, C(CN)2, NCOR2, NCO2 R2, NSO2 R2 or NR3 in which R2 is (C1-6)alkyl or (C6-12)aryl and R3 is H or C1-6)alkyl; B is (C1-6)alkoxy, (C1-6)alkylthio or NR4 R5 in which R4 and R5 are independently H, (C1-10)alkyl, C3-6 (alkenyl), (C3-6)alkynyl, (C2-6)(primary hydroxy)alkyl, (C2-6)(primary amino)alkyl or C3-6)cycloalkyl or R4 and R5 are joined to form a 5- or 6- membered saturated ring optionally containing an additional O or NH: and the salts thereof.